The Effect of St John's Wort on the Pharmacodynamic Response of Clopidogrel in Hyporesponsive Volunteers and Patients: Increased Platelet Inhibition by Enhancement of CYP3A4 Metabolic Activity

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of Cardiovascular Pharmacology

• Publication date

  2011-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/FJC.0b013e3181ffe8d0PMID 20980920
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.

  2010cited by this paper
• Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.

  2009cited by this paper
• Ticagrelor versus clopidogrel in patients with acute coronary syndromes.

  2009cited by this paper
• Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent.

  2009cited by this paper
• Dose Effect of Clopidogrel Reloading in Patients Already on 75-mg Maintenance Dose: The Reload With Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term With Dual Antiplatelet Therapy (RELOAD) Study

  2008cited by this paper
• Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study.

  2008cited by this paper
• St John's wort for major depression.

  2008cited by this paper
• Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.

  2008cited by this paper
• Prasugrel versus clopidogrel in patients with acute coronary syndromes.

  2007cited by this paper
• A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation.

  2007cited by this paper
• Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis.

  2007cited by this paper
• Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects.

  2006cited by this paper
• Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets: Results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) Study

  2005cited by this paper
• Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study.

  2005cited by this paper
• Randomized Trial of High Loading Dose of Clopidogrel for Reduction of Periprocedural Myocardial Infarction in Patients Undergoing Coronary Intervention: Results From the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study*

  2005cited by this paper
• Contribution of Hepatic Cytochrome P450 3A4 Metabolic Activity to the Phenomenon of Clopidogrel Resistance

  2004cited by this paper
• Clopidogrel Resistance Is Associated With Increased Risk of Recurrent Atherothrombotic Events in Patients With Acute Myocardial Infarction

  2004cited by this paper
• St John's wort induces both cytochrome P450 3A4–catalyzed sulfoxidation and 2C19–dependent hydroxylation of omeprazole

  2004cited by this paper
• The Influence of St. John's Wort on CYP2C19 Activity with Respect to Genotype

  2004cited by this paper
• Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement

  2003cited by this paper
• Atorvastatin Reduces the Ability of Clopidogrel to Inhibit Platelet Aggregation: A New Drug–Drug Interaction

  2003cited by this paper
• Clopidogrel for Coronary Stenting Response Variability, Drug Resistance, and the Effect of Pretreatment Platelet Reactivity

  2003cited by this paper
• 2.1 A crystal structure of human PXR in complex with the St. John's wort compound hyperforin.

  2003influential reference
• Short-Course Rifampin and Pyrazinamide Compared with Isoniazid for Latent Tuberculosis Infection: A Multicenter Clinical Trial

  2002cited by this paper
• Herb-drug interactions: review and assessment of report reliability.

  2001cited by this paper
• St John's Wort: effect on CYP3A4 activity.

  2000cited by this paper
• St John's Wort induces intestinal P‐glycoprotein/MDR1 and intestinal and hepatic CYP3A4

  2000cited by this paper
• St John's Wort: Effect on CYP3A4 activity

  2000cited by this paper
• St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor.

  2000cited by this paper
• Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel.

  1999cited by this paper
• Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-III Investigators. Global Use of Strategies to Open Occluded Coronary Arteries.

  1998cited by this paper
• Book Reviews

  1998cited by this paper
• CYP3A4 and the erythromycin breath test

  1998cited by this paper
• Noninvasive tests of CYP3A enzymes.

  1994cited by this paper

• Herb-drug interaction of Astragali Radix based on in vitro incubation and pharmacokinetic assessment

  2025cites this paper
• Understanding Drug Interactions in Antiplatelet Therapy for Atherosclerotic Vascular Disease: A Systematic Review

  2025cites this paper
• Use of herbal remedies in chronic heart diseases

  2024cites this paper
• Documentary Analysis of Hypericum perforatum (St. John’s Wort) and Its Effect on Depressive Disorders

  2024cites this paper
• Platelet antiaggregant activity of Hypericum perforatum extracts

  2024cites this paper
• Utility of Therapeutic Drug Monitoring in Identifying Clinically Significant Interactions Between St. John's Wort and Prescription Drugs

  2023cites this paper
• Pharmacokinetic and pharmacodynamic herb-drug interactions—part I. Herbal medicines of the central nervous system

  2023cites this paper
• Herb-Drug Interactions and Their Impact on Pharmacokinetics: an Update.

  2023cites this paper
• Drug-Herb Synergistic Interactions between Clopidogrel and Natural Medicine.

  2023cites this paper
• Antiplatelet and myocardial protective effect of Shexiang Tongxin Dropping Pill in patients undergoing percutaneous coronary intervention: A randomized controlled trial.

  2022cites this paper
• Hypericum perforatum: Traditional uses, clinical trials, and drug interactions

  2022cites this paper
• Clinical pharmacology of antiplatelet drugs

  2022cites this paper
• Evaluation of the Herb-Drug Interaction Potential of Commonly Used Botanicals on the US Market with Regard to PXR- and AhR-Mediated Influences on CYP3A4 and CYP1A2

  2022cites this paper
• Clinical and Pharmacological Parameters Determine Relapse During Clopidogrel Treatment of Acute Coronary Syndrome

  2021cites this paper
• Drug–Drug Interactions With Over-The-Counter Medicines: Mind the Unprescribed

  2021cites this paper
• The Prescription of Drug Ontology 2.0 (PDRO): More Than the Sum of Its Parts

  2021cites this paper
• St John’s wort (Hypericum perforatum L)

  2021cites this paper
• Herbal Substances that Affect Hemostasis

  2021cites this paper
• Concomitant botanical medicine use among patients participating in commercial prostate cancer trials.

  2020cites this paper
• Clopidogrel drug interactions: a review of the evidence and clinical implications

  2020cites this paper
• Plant Metabolomics and Quality Evaluation of Herbal Drugs

  2019cites this paper
• [A Survey of Health Food Use and Patient Satisfaction among Patients Undergoing Cancer Pharmacotherapy].

  2019cites this paper
• Physiologically Based Pharmacokinetic Modelling of Hyperforin to Predict Drug Interactions with St John’s Wort

  2019cites this paper
• Understanding drug interactions with St John's wort (Hypericum perforatum L.): impact of hyperforin content

  2019cites this paper
• Potential Pharmacokinetic Herb-Drug Interactions: Have we Overlooked the Importance of Human Carboxylesterases 1 and 2?

  2019cites this paper
• Antithrombotic Therapy in Patients with ST-segment Elevation Myocardial Infarction Undergoing Primary PCI

  2019cites this paper
• Interaction Between Traditional Chinese Medicine and Anticoagulant/antiplatelet Drugs.

  2019cites this paper
• Interactions between clopidogrel and traditional Chinese medicine

  2019cites this paper
• PON-1 Q 192 R ( rs 662 ) Gene Polymorphism and The Risk of Major Adverse Cardiovascular Events in Clopidogrel-Treated Patients with Coronary Heart Disease : A Systematic Review and Meta-Analysis

  2019cites this paper
• Effects of Danshen capsules on the pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.

  2018cites this paper
• Enzyme Kinetics and Molecular Docking Studies on Cytochrome 2B6, 2C19, 2E1, and 3A4 Activities by Sauchinone

  2018cites this paper
• CYP2C19 or CYP3A5 Genotyping Does Not Predict Clinical Response to Clopidogrel

  2018cites this paper
• A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Study of the Effects of Tongxinluo Capsules in Acute Coronary Syndrome Patients with High On-Treatment Platelet Reactivity

  2018cites this paper
• Pharmacokinetic Interactions and Pharmacogenetics of Clopidogrel, Prasugrel and Ticagrelor

  2018cites this paper
• Elucidation of Factors Influencing Use of Health Foods and Supplements in Cancer Patients

  2018cites this paper
• Cardiovascular Toxicities of Herbal Products: An Overview of Selected Compounds

  2017cites this paper
• Natural Products with Antiplatelet Action.

  2017cites this paper
• What risks do herbal products pose to the Australian community?

  2017cites this paper
• What risks do herbal products pose to the Australian community?

  2017cites this paper
• Clinical risks of St John’s Wort (Hypericum perforatum) co-administration

  2017cites this paper
• Effect of dietary flavonoids on hepatic CYP 2 E 1 and 3 A 4 activity – Implication for food-drug interactions

  2017cites this paper
• Influencia de seis polimorfismos del metabolismo de clopidogrel sobre la reactividad plaquetaria en pacientes con síndrome coronario agudo

  2017cites this paper
• Monitoring of Antiplatelet Therapy

  2017cites this paper
• A Comprehensive Review of Recent Studies on Herb-Drug Interaction: A Focus on Pharmacodynamic Interaction

  2016cites this paper
• Altered Expression/Activity of Cytochrome P450 (CYP) 3A4 Enzyme:Implications in Drug Safety and Efficacy

  2016cites this paper
• The Influence of Herbal Medicine on Platelet Function and Coagulation: A Narrative Review

  2015cites this paper
• Interactions between CYP3A4 and Dietary Polyphenols

  2015cites this paper
• Natural products-friends or foes?

  2015cites this paper
• Reduction of hyperbilirubinemia with hypericum extract (St. John's Wort) in a patient with Crigler‐Najjar syndrome type II

  2015cites this paper
• P2Y12 antagonists in non-ST-segment elevation acute coronary syndromes: latest evidence and optimal use

  2015cites this paper
• Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy

  2015cites this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel

  2015cites this paper
• AN IN VITRO INVESTIGATION INTO THE MECHANISM OF THE CLINICALLY RELEVANT DRUG-DRUG INTERACTION BETWEEN OMEPRAZOLE OR ESOMEPRAZOLE AND CLOPIDOGREL

  2015cites this paper
• Other Drug Interactions with Clopidogrel

  2014cites this paper
• Resistance to antiplatelet drugs: what progress has been made?

  2014cites this paper
• Tratamiento antiagregante plaquetario personalizado

  2014cites this paper
• A Review of Herbal Interactions with Antiplatelet Drugs

  2014cites this paper
• Drugs that affect blood coagulation, fibrinolysis, and hemostasis

  2014cites this paper
• Farmakokinetyka kliniczna klopidogrelu i jego metabolitów z uwzględnieniem polimorfizmu genetycznego izoenzymu CYP2C19 i glikoproteiny P

  2014cites this paper
• A randomized controlled trial of adjunctive Bunchang Naoxintong Capsule (步长脑心通胶囊) versus maintenance dose clopidogrel in patients with CYP2C19*2 polymorphism

  2014cites this paper
• Update: Acute coronary syndromes (V). Personalized antiplatelet therapy.

  2014cites this paper
• In vitro assessment of some traditional medications used in South Africa for pharmacokinetics drug interaction potential

  2013cites this paper
• St. John’s Wort in Patients Non-responders to Clopidogrel Undergoing Percutaneous Coronary Intervention: a Single-Center Randomized Open-Label Trial (St. John’s Trial)

  2013cites this paper
• Interactions with Drugs and Dietary Supplements Used For Weight Loss

  2013cites this paper
• Pharmacogenomics and Personalized Medicine of the Antiplatelet Drugs

  2013cites this paper
• Clopidogrel, CYP2C19, and a Black Box

  2013cites this paper
• Hepatic activation of irinotecan predicts tumour response in patients with colorectal liver metastases treated with DEBIRI: exploratory findings from a phase II study

  2013cites this paper
• Antiplatelet drug resistance and variability in response: the role of antiplatelet therapy monitoring.

  2013cites this paper
• Assessment of bleeding risk of interventional techniques: a best evidence synthesis of practice patterns and perioperative management of anticoagulant and antithrombotic therapy.

  2013cites this paper
• Influence of the paraoxonase‐1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta‐analysis

  2012cites this paper
• Prevalence of poor biological response to clopidogrel

  2012cites this paper
• Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome?

  2012cites this paper
• Beneficial Pharmacokinetic Drug Interactions

  2012cites this paper
• Drug Interactions with Herbal Medicines

  2012cites this paper
• Pharmacogenomics Dictate Pharmacokinetics: Polymorphisms in Drug-Metabolizing Enzymes and Drug-Transporters

  2012cites this paper
• Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study.

  2012influential citation
• An update on the ability of St. John's wort to affect the metabolism of other drugs

  2012cites this paper
• Pharmacokinetics-pharmacology disconnection of herbal medicines and its potential solutions with cellular pharmacokinetic-pharmacodynamic strategy.

  2012cites this paper
• In Vitro Assessment of Cytochrome P450 2C19 Potential of Naoxintong

  2012cites this paper
• Latest Evidence in Personalized Antiplatelet Therapy in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention

  2012cites this paper
• An Overview of the Evidence and Mechanisms of Herb–Drug Interactions

  2012cites this paper
• Botanical-Drug Interactions: A Scientific Perspective

  2012cites this paper
• Genetic and non-genetic factors affecting the response to clopidogrel therapy

  2012cites this paper
• Advances in Pharmacoepidemiology & Drug Safety

  2012cites this paper
• Significance of clopidogrel resistance related to the stent-assisted angioplasty in patients with atherosclerotic cerebrovascular disease.

  2011cites this paper
• Cytochrome P450 2C19 Polymorphism in Iranian Patients with Coronary Artery Disease

  2011cites this paper
• Clinical herbal interactions with conventional drugs: from molecules to maladies.

  2011cites this paper
• Clopidogrel-drug interactions.

  2011cites this paper
• Resistance to Antiplatelet Therapy

  2011cites this paper
• Clopidogrel and proton pump inhibitors: influence of pharmacological interactions on clinical outcomes and mechanistic explanations.

  2011cites this paper
• Clinical Pharmacology: Advances and Applications Dovepress Cytochrome P450 3a4*22, Ppar-α, and Arnt Polymorphisms and Clopidogrel Response

  year unknowncites this paper